Vutrisiran (Amvuttra) for Hereditary ATTR Amyloidosis Polyneuropathy

A woman I met at a support group last year — I'll call her Ellen — spent almost six years being told her progressive numbness, weakness, and unsteady gait were “just idiopathic neuropathy.” Six years. She'd tried gabapentin, alpha-lipoic acid, physical therapy, three different neurologists, and a diet that eliminated everything short of oxygen. Then a young resident asked one question nobody else had thought to ask: did anyone in her family have unexplained heart failure or neuropathy? Two months later, genetic testing confirmed she carried a mutation in the TTR gene. She had hereditary transthyretin-mediated amyloidosis, or hATTR. And for the first time in six years, there was a treatment she could actually start.

That treatment was vutrisiran — brand name AMVUTTRA — the newest siRNA drug approved for hATTR polyneuropathy. It was Ellen's second-opinion neurologist who explained what it does in language she could actually use: it silences the gene that's making the bad protein, so the nerves stop getting new damage. She started injections a few months later. Today, over a year in, she says the progression has stopped. Not reversed — the damage that's already there is still there — but stopped. For someone who'd watched herself deteriorate for six years, “stopped” was a word that changed everything.

Vutrisiran isn't a cure, and it isn't for most people with neuropathy. But if you or someone you love is dealing with unexplained progressive polyneuropathy — the kind that keeps getting worse without a clear cause — it belongs on your radar. This is the article I wish Ellen had found five years earlier.

What hATTR Amyloidosis Actually Is

Hereditary transthyretin-mediated amyloidosis is a mouthful, so let me unpack it piece by piece.

Your liver makes a protein called transthyretin, or TTR for short. Its normal job is to carry thyroid hormone and vitamin A around your bloodstream. In most people, TTR does that quietly for a lifetime and nobody thinks about it. But some people are born with a mutation in the TTR gene — one of more than 100 known variants — that makes the protein unstable. Instead of folding neatly and doing its delivery job, the misfolded protein clumps together into sticky deposits called amyloid fibrils. Those deposits build up in tissues over the years and cause damage.

When amyloid deposits collect on peripheral nerves, the result is hATTR polyneuropathy — the “hATTR-PN” you'll see in medical literature. When they collect in the heart muscle, the result is hATTR cardiomyopathy (hATTR-CM). Many people end up with both, sometimes at the same time and sometimes years apart.

The “hereditary” part matters because the mutation is passed from parent to child, and each first-degree relative of someone with the diagnosis has a 50% chance of carrying it. That's why one confirmed diagnosis in a family often opens the door to genetic counseling and testing for parents, siblings, and adult children. There's also a non-hereditary form — wild-type ATTR — where the normal (non-mutated) protein becomes unstable with age. That form mostly affects the heart, though it can cause carpal tunnel syndrome and some peripheral neuropathy in older adults. Vutrisiran was initially approved specifically for the hereditary polyneuropathy form, and that's the version we're focused on today.

If you'd like a fuller picture of the condition itself, we have a companion article on ATTR amyloid neuropathy that goes deeper into diagnosis, genetics, and the full clinical landscape. This one is focused specifically on the drug.

How TTR Amyloid Damages Nerves (and Why It's Missed)

To understand what vutrisiran does, it helps to understand what it's up against. Amyloid deposits on peripheral nerves don't damage them all at once. It's a slow, insidious accumulation. Year after year, more and more fibrils settle in and around the nerve fibers — first the small unmyelinated fibers that carry pain and temperature signals, then the larger fibers that carry proprioception and motor commands.

That's why hATTR neuropathy so often starts as burning feet, numb toes, or vague pain that a general neurologist can easily mistake for small-fiber neuropathy of unknown cause. Over the next few years, larger fibers get involved. Balance deteriorates. Legs get weak. Autonomic symptoms creep in — orthostatic dizziness, GI slowing, bladder issues, erectile dysfunction in men. Many patients also develop autonomic neuropathy that touches nearly every system in the body.

The reason this diagnosis gets missed for years — sometimes six or seven years, sometimes longer — is that it mimics so many more common conditions. Doctors see progressive polyneuropathy every day. Nine times out of ten, it's diabetes, alcohol, a B-vitamin deficiency, a chemotherapy history, or something they can point at. The one time out of ten it's hATTR, the fingerprint gets lost in the noise. Patients accumulate labels like idiopathic neuropathy or “chronic sensory-motor polyneuropathy, cause unclear” and move from one specialist to another without ever getting the specific genetic test that would end the mystery.

The good news is that specialists have started to recognize a cluster of clues — what neurologists sometimes call the “hATTR phenotype.” If a patient has progressive polyneuropathy plus a family history of neuropathy, unexplained heart failure, or early bilateral carpal tunnel — especially in both hands before age 60 — the suspicion for hATTR goes way up. And when the suspicion is there, the answer is a straightforward blood-based genetic test.

What Vutrisiran Does — RNA Interference Explained

Here is where the story gets genuinely futuristic. Vutrisiran is not like the drugs most of us grew up with. It doesn't block a receptor, kill a bacterium, or dial down inflammation. It reaches into your liver cells and switches off the gene that's making the bad protein in the first place.

Here's the plain-English version of how RNA interference — RNAi — works. Genes live in your DNA. To make a protein, your cell copies the relevant piece of DNA into a working blueprint called messenger RNA, or mRNA. That mRNA then travels to the cell's protein-building machinery, which reads the blueprint and assembles the actual protein. Vutrisiran is a tiny piece of RNA custom-designed to match the TTR mRNA blueprint. When it finds that blueprint inside a liver cell, it flags it for destruction. The blueprint gets shredded before the cell can build the protein.

The result: your liver produces dramatically less TTR protein. In clinical trials, serum TTR levels dropped by about 83% on average and stayed there. Less TTR in the blood means less TTR available to misfold into amyloid, which means the ongoing damage to nerves and heart slows dramatically.

One elegant piece of the design: vutrisiran is chemically attached to a molecule called GalNAc that liver cells recognize and pull inside. That means the drug is delivered directly and specifically to hepatocytes — the liver cells that make almost all your body's TTR — without needing to reach every cell in the body. It's targeted molecular delivery, which is part of why it can be given as a small injection under the skin rather than an IV infusion.

A fair question: what about the TTR your body still needs to carry thyroid hormone and vitamin A? The remaining 15-20% of normal TTR production is enough to handle those transport jobs for most people. The one caveat is that patients on vutrisiran are asked to take a daily vitamin A supplement at the recommended daily allowance to make sure retinol levels stay in a healthy range.

How Vutrisiran Compares to Patisiran and Eplontersen

Vutrisiran isn't the only drug in this space. Understanding where it fits helps a lot when you're sitting in the specialist's office trying to make sense of options.

Patisiran (ONPATTRO) was the first TTR-silencing drug FDA-approved for hATTR polyneuropathy, back in 2018. It's also an siRNA — same general approach as vutrisiran. But it's delivered as an intravenous infusion every three weeks, packaged inside tiny lipid particles that carry it to the liver. That's a lot of infusion center visits — around 17 per year — and each one requires premedication with steroids and antihistamines to prevent infusion reactions. It works. It's also a serious quarterly commitment of time and energy. Some patients did (and still do) very well on it, but the logistics are real.

Vutrisiran (AMVUTTRA) is essentially the next-generation version. Same silencing approach, but the GalNAc chemistry lets it be given as a small subcutaneous injection every three months — four injections per year, no infusion center, no premedication. For a person who's still working, or driving long distances to see a specialist, or dealing with the fatigue that comes with any chronic disease, that difference matters enormously.

Inotersen (TEGSEDI) was FDA-approved the same year as patisiran. It's a different molecular class — an antisense oligonucleotide (ASO) rather than an siRNA. It works on TTR mRNA too, but through a different pathway. Inotersen is a weekly subcutaneous injection and has a black box warning for low platelets and kidney effects, requiring routine monitoring. In practice, it's been overtaken by newer options in most treatment programs.

Eplontersen (WAINUA) is the newer ASO, FDA-approved in late 2023 for hATTR polyneuropathy. Like vutrisiran, it uses GalNAc targeting for liver delivery and is given as a small subcutaneous injection — once monthly rather than quarterly. It doesn't carry the platelet or kidney warning that inotersen did. Head-to-head data against vutrisiran doesn't exist, so choice often comes down to dosing preference, insurance formulary, and the treating specialist's experience.

Then there's tafamidis (VYNDAQEL, VYNDAMAX), an oral pill that works differently — it stabilizes the TTR protein so it doesn't misfold in the first place, rather than silencing it. In the United States, tafamidis is approved for the cardiomyopathy of ATTR, not the polyneuropathy form. It comes up in ATTR-CM conversations but isn't a direct alternative to vutrisiran for polyneuropathy patients.

What the HELIOS-A Trial Data Showed

The pivotal trial for vutrisiran in polyneuropathy was called HELIOS-A. It enrolled 164 adults with hATTR-PN and randomized them into two treatment arms — vutrisiran or patisiran as an active comparator — with the placebo comparison drawn from patients who'd been on placebo in an earlier patisiran trial called APOLLO. That's called an external placebo comparison, and it's not unusual in rare-disease research where it would be ethically difficult to leave people untreated for 18 months when treatments exist.

The primary endpoint was a neuropathy severity score called mNIS+7 — a composite of physical exam findings, sensory testing, and nerve conduction measures. Higher scores mean worse neuropathy. In the external placebo group, mNIS+7 scores got worse over 9 and 18 months, as you'd expect for an untreated progressive disease. In the vutrisiran group, scores actually improved on average — that is, patients got measurably better, not just slower to worsen. The difference between the two groups was substantial and statistically significant.

Secondary endpoints looked at quality of life (a validated questionnaire called Norfolk QOL-DN), gait speed, and nutritional status. All of them favored vutrisiran meaningfully. The drug also produced a rapid and durable reduction in serum TTR of about 83% on average — showing that the silencing effect works exactly as designed.

An honest caveat: HELIOS-A was an 18-month study. Longer-term data — how patients do over 5, 10, or 20 years — is still being collected. What the trial did establish is that vutrisiran meaningfully slows and, for many patients, modestly reverses the neuropathy progression of hATTR over the study window. For a disease that used to be relentlessly progressive, that's a big deal. The broader question of whether nerve damage can ever be truly undone is one we've written about in can neuropathy be reversed — the honest answer for most neuropathies is “not fully, but progression can often be halted,” and vutrisiran fits that pattern.

How the Injection Works and What Treatment Looks Like

Practically speaking, being on vutrisiran doesn't look like being on most medications. There's no daily pill, no weekly reminder, no IV chair for hours at a time. Every three months, you go into your specialist's office or an infusion center, a nurse gives you a small subcutaneous injection — usually in the abdomen or upper thigh — and you go home. The injection itself takes about five minutes. Some patients describe a brief pinch or sting; most say it's uncomfortable but not painful.

There's no required premedication, no need for steroids or antihistamines beforehand. You don't have to fast. You can drive yourself home. Most people go back to work the same afternoon.

A typical treatment year is four appointments. That's it. Compared to the previous generation of TTR-targeted therapy, this is a genuine quality-of-life difference. Many patients I've spoken with describe the shift from patisiran (17 IV infusions a year) to vutrisiran as one of the biggest gifts the field has given them.

What happens on the drug: labs check TTR levels and confirm the silencing effect is working. Symptoms — burning, numbness, weakness, autonomic complaints — are tracked over months. For most patients the trajectory of the disease bends. Progression slows or halts. For some, particularly those started earlier in the course of disease, meaningful improvement in symptoms and function is possible. For those started later, the goal is often stabilization — preserving what's still there.

Living with a progressive disease is its own kind of work, and the psychological weight of it is real. If you're facing a new diagnosis or grappling with the emotional load of managing a chronic condition, please see our piece on neuropathy and mental health. You're not the only one carrying this.

Who Qualifies for Amvuttra — Testing and Diagnosis

Vutrisiran isn't a drug you start based on symptoms alone. The FDA approval is specifically for adults with the polyneuropathy of hereditary ATTR amyloidosis, which means you need three things confirmed before treatment begins.

1. A confirmed TTR gene mutation. This is a blood test — a targeted genetic sequencing of the TTR gene. You give a tube of blood, the lab sequences the gene, and either they find a known pathogenic variant or they don't. It's about as definitive a test as medicine offers. Genetic counseling is typically offered alongside testing, both because of what the result means for you and because a positive result has implications for your children, siblings, and parents.

2. Confirmed peripheral neuropathy linked to the mutation. This usually involves nerve conduction studies, electromyography (EMG), and a thorough neurologic exam. Sometimes a nerve biopsy is used to look for amyloid deposits under a microscope with a special stain called Congo red. Sometimes a specialty PET or SPECT scan is used to look at organ involvement. The point is to confirm that the neuropathy you have is being driven by the amyloid deposition — not just that you carry the mutation.

3. Adult status and no contraindications. Vutrisiran is approved for adults. There are no absolute contraindications beyond a known severe hypersensitivity to the drug itself, but the specialist will review your full history — kidney function, liver function, other medications — before starting.

The specialist doing this work is usually a neurologist with expertise in amyloidosis, or a physician at one of the growing number of amyloidosis centers around the country. If you're not sure whether your current neurologist is set up to handle hATTR, ask directly: “Do you manage patients on siRNA therapies for ATTR polyneuropathy?” It's an entirely reasonable question, and a specialist who doesn't will usually refer you to someone who does. For a broader look at how neuropathy gets worked up in the first place, see how neuropathy is diagnosed.

One more note on timing. hATTR is a progressive disease, and there's a growing consensus among amyloidosis specialists that earlier treatment leads to better outcomes. Nerves that are lost don't come back easily. If you or a family member has been diagnosed and treatment hasn't started, ask why. And if you've received a diagnosis of “idiopathic” or unexplained progressive neuropathy — especially at any of the stages of neuropathy where symptoms are advancing — asking about TTR testing is a completely appropriate conversation.

Side Effects, Cost, and Access

Vutrisiran has a favorable safety profile compared to some of the earlier options in this class. The most common side effects reported in the HELIOS-A trial were pain in the arms or legs, joint pain, mild shortness of breath, and occasional injection site reactions — usually mild redness or brief tenderness at the injection spot. Vitamin A levels drop on the drug because TTR carries retinol-binding protein through the bloodstream, which is why patients are asked to take a daily vitamin A supplement at the recommended daily allowance.

There's no black box warning. There's no required lab monitoring for platelets or kidney function the way there is with the older inotersen. Most patients tolerate vutrisiran without significant issues, which is one of the reasons it has become the default choice for many amyloidosis specialists when starting treatment.

Now the harder part: cost. The list price of vutrisiran is roughly $463,500 per year. That's four quarterly doses at around $115,000 each. Yes, you read that correctly. It's an orphan drug for a rare disease, and it's priced accordingly. Very few patients pay anything close to list price, but the sticker on the shelf is real.

In practice, insurance coverage is where the real story is:

• Medicare Part B typically covers vutrisiran as a physician-administered medication, since it's given by injection in a healthcare setting. Beneficiaries pay a 20% coinsurance unless they have supplemental coverage.
• Commercial insurance usually covers it with prior authorization, which requires documentation of the genetic diagnosis and confirmed polyneuropathy.
• Alnylam Assurance, the manufacturer's patient support program, helps navigate prior authorization, provides copay assistance for eligible commercial patients, and offers a free-drug program for eligible uninsured patients who meet income criteria.

In real-world use, most patients ultimately pay a manageable amount out of pocket — sometimes very little — but the process of getting there can take weeks and involves a lot of paperwork. Amyloidosis specialty centers usually have dedicated staff who navigate this daily, which is another reason to be treated at a center that sees a lot of hATTR patients. If cost feels like an immovable barrier, tell the specialist's office. They have options and workarounds that individual patients often don't know about.

Frequently Asked Questions

Is vutrisiran a cure for hATTR amyloidosis?

No. Vutrisiran silences the production of the TTR protein so that new amyloid deposits are dramatically reduced, but it doesn't remove amyloid that has already accumulated in nerves or the heart, and it doesn't correct the underlying genetic mutation. It slows or halts progression of the disease and can produce modest improvement in neuropathy scores over the first 18 months of treatment. It's a durable treatment, not a cure.

How is vutrisiran different from patisiran?

Both drugs are siRNA therapies that silence TTR production in the liver. Patisiran is delivered as an intravenous infusion every three weeks and requires premedication with steroids and antihistamines to prevent infusion reactions. Vutrisiran is a subcutaneous injection every three months and requires no premedication. The clinical effect is broadly similar, but the practical burden is much lower for vutrisiran, which is why it has become the more commonly chosen option for new starts.

Can vutrisiran reverse existing nerve damage?

Partial improvement is possible. The HELIOS-A trial showed that neuropathy severity scores actually improved in the vutrisiran group over 18 months, rather than just slowing worsening. That said, nerve regeneration is slow, and the earlier treatment begins in the course of disease, the better the chances of preserving and recovering function. Damage that has been present for many years is less likely to reverse than damage caught early.

How often do I need injections?

Once every three months, so four times per year. Each dose is 25 milligrams given as a subcutaneous injection by a healthcare professional. The injection itself takes about five minutes and you can typically go about your day afterward. There is no required fasting or premedication.

What are the most common side effects?

The most commonly reported side effects in clinical trials were pain in the arms or legs, joint pain, mild shortness of breath, and occasional mild injection site reactions such as redness or brief tenderness. Vitamin A levels drop while on treatment, which is why patients are asked to take a daily vitamin A supplement at the recommended daily allowance. There is no black box warning and no routine platelet or kidney monitoring is required.

Do my children need to be tested if I have hATTR?

This is a conversation to have with a genetic counselor. Each first-degree relative — parents, siblings, and children — has a 50% chance of carrying the same mutation. Adult family members can choose whether to be tested, and there are meaningful pros and cons on both sides. Genetic counseling before and after testing is strongly recommended so that the decision, whichever way it goes, is made with full understanding of the implications.

What if I've been told I have idiopathic neuropathy but I have a family history of unexplained illness?

Ask your neurologist about TTR genetic testing. The combination of progressive polyneuropathy plus family history of neuropathy, unexplained heart failure, or bilateral carpal tunnel syndrome is exactly the constellation that amyloidosis specialists look for. A blood-based genetic test is the definitive answer, and it takes minutes to order. Getting a clear yes or no changes everything about what happens next.

How much does vutrisiran cost?

The list price is roughly $463,500 per year, but very few patients pay anywhere near that. Medicare Part B typically covers it as a physician-administered medication, most commercial insurance plans cover it with prior authorization, and the manufacturer's patient support program offers copay assistance and a free-drug program for eligible uninsured patients. If cost feels like a barrier, the specialist's office and the manufacturer's assistance program are where the real answer lives.

About the Author

View All Posts